Ascendis Pharma Oncology Division A/S: Financial statements 2025
CVR: 41034076
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Ascendis Pharma Oncology Division A/S (CVR 41034076) has filed annual accounts for 2025. In 2025, the company reported a gross profit of EUR -85,226,000 and a net result of EUR -110,131,000 compared with EUR -106,375,000 the year before. Equity in the 2025 report amounted to EUR -501,637,000.
- Gross Profit
- EUR -85,226,000
- Profit/Loss
- EUR -110,131,000
- Equity
- EUR -501,637,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -85.2M EUR | -110.1M EUR | -501.6M EUR | 0 |
| 2024 | - | -92.5M EUR | -106.4M EUR | -391.5M EUR | 0 |
| 2023 | - | -140.1M EUR | -144.1M EUR | -285.1M EUR | 0 |
| 2022 | - | -62.4M EUR | -64.9M EUR | -141M EUR | 0 |
| 2021 | - | -46.7M EUR | -48M EUR | -76.1M EUR | 0 |
Official annual report
How creditworthy is Ascendis Pharma Oncology Division A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Ascendis Pharma Oncology Division A/S has published its annual report for 2024. Gross profit came to DKK -92,475,000, and the net result was DKK -106,375,000.
About Ascendis Pharma Oncology Division A/S
Ascendis Pharma Oncology Division A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -85,226,000 and a net result of EUR -110,131,000 compared with EUR -106,375,000 the year before. Equity in the 2025 report amounted to EUR -501,637,000.
